HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Prolymphocytic leukemia — Clinical Guidelines

Overview

Prolymphocytic leukemia (PLL) is a rare, aggressive lymphoid malignancy characterized by prolymphocytes, with distinct subtypes in B-cells and T-cells. It carries a poor prognosis with limited curative therapies available 1.

Diagnosis

Morphologic identification of prolymphocytes in peripheral blood or bone marrow

Immunophenotypic analysis to differentiate B-PLL and T-PLL

Cytogenetic and molecular studies to detect abnormalities like TP53 mutations 1

Cytochemical and immunochemical studies to rule out pseudohyperkalaemia and misdiagnosis of acute leukemia 2 3

Transmission electron microscopy for identifying rare cytoplasmic inclusions 4

Management

B-PLL: Rituximab-based combination chemoimmunotherapy for fit patients; alemtuzumab for TP53 abnormalities 1

T-PLL: Frontline treatment with intravenous alemtuzumab, achieving high response rates >90% 1

Consolidation: Autologous or allogeneic stem cell transplantation to prolong survival, with allogeneic potentially curative 1

Monitoring: Regular assessment for pseudohyperkalaemia due to lymphocyte lysis in vitro 3

Special Populations

No specific guidelines provided for pregnancy, pediatrics, or elderly patients in the abstracts 1 2 3 4

Key Recommendations

Use rituximab-based chemoimmunotherapy for fit B-PLL patients with consideration of alemtuzumab in those with TP53 abnormalities (Evidence: Moderate) 1

Initiate frontline treatment with intravenous alemtuzumab for T-PLL to achieve high response rates (Evidence: Moderate) 1

Consider autologous or allogeneic stem cell transplantation for consolidation of remission in PLL, with allogeneic potentially offering curative potential (Evidence: Expert opinion) 1

References

1 Dearden C. B- and T-cell prolymphocytic leukemia: antibody approaches. Hematology. American Society of Hematology. Education Program 2012. link 2 Juneja HS, Rajaraman S, Alperin JB, Bainton DF. Auer rod-like inclusions in prolymphocytic leukemia. Acta haematologica 1987. link 3 Zaltzman M, Bezwoda WR. Hyperkalaemia in prolymphocytic leukaemia--a sometimes spurious result. A case report. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1982. link 4 Costello C, Catovsky D, O'Brien M. Cytoplasmic inclusions in a case of prolymphocytic leukemia. American journal of clinical pathology 1981. link

Prolymphocytic leukemia